Recent Updates — SNTI
Edward Mathers notified the Board of Directors on October 27, 2026, of his decision to resign from the board and all committee positions, effective immediately. The company thanked him for his service. Additionally, the filing confirms the record date of October 30, 2026, for a previously announced distribution of contingent value rights (CVRs) related to the merger closing on October 21, 2026. Senti Biosciences Holdings operates in the biotechnology sector, focusing on synthetic biology and cell therapy.
On October 21, 2026, Senti Biosciences Holdings completed a merger with ST NewCo Limited (f/k/a Celadon Partners SPV 35 Limited), resulting in the divestiture of its entire ownership interest in Midco and Opco. Shareholders received Contingent Value Rights entitling them to up to $60 million in milestone payments for SENTI-202, including $10 million upon FDA BLA acceptance, $20 million upon approval, and $30 million if net sales exceed $200 million. The company also issued 7,309,941 shares to an affiliate of Celadon Partners for approximately $2.5 million in proceeds. Additionally, the company forced the exchange of $16 million in Senior Secured Convertible Notes into common stock at $0.342 per share. Senti Biosciences operates as a biotechnology company developing cell therapies and immunotherapies.
Senti Biosciences Holdings stockholders approved the Agreement and Plan of Merger with ST NewCo Limited, enabling the acquisition. The vote also authorized a reverse stock split ranging from 1-for-20 to 1-for-50 at the Board's discretion and permitted share issuance exceeding 19.99% upon conversion of Senior Secured Convertible Notes. Three directors were elected and KPMG was reappointed as auditor. Senti Biosciences Holdings operates in the biotechnology sector, focusing on synthetic biology and gene editing technologies.
Senti Biosciences Holdings convened its virtual 2026 Annual Meeting of Stockholders but adjourned without conducting business to allow more time to solicit shareholder support for the Merger Agreement Proposal. The meeting will reconvene on October 15, 2026, at 8:00 a.m. Pacific time via the internet. No changes have been made to the proposals, and polls remain open. Senti Biosciences is a synthetic biology company developing engineered cell therapies.
On September 23, 2026, Brenda Cooperstone, Ph.D., resigned from the Board of Directors and as Chair of the Compensation Committee at Senti Biosciences Holdings, Inc., effective immediately. The company stated that her departure was not due to any disagreements regarding operations or policies. Senti Biosciences is a synthetic biology company focused on developing engineered cell therapies.
On September 3, 2026, Senti Biosciences Holdings completed the issuance of $2.0 million in Senior Secured Convertible Notes to NSG BioInnovation Fund under a Securities Purchase Agreement dated April 27, 2026. The company also entered into an equity commitment letter with an affiliate of Celadon Partners, LLC, agreeing to sell $2.5 million of common stock at the Nasdaq Minimum Price around the time of a merger closing. These transactions are part of broader Subject Transactions involving a potential merger and contingent value rights that may pay up to $60.0 million based on regulatory and sales milestones for product candidate SENTI-202. A preliminary proxy statement was filed on July 21, 2026, with definitive materials expected soon. Senti Biosciences Holdings operates in the biotechnology industry, developing immunotherapies.